InflaRx (NASDAQ:IFRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

InflaRx Price Performance

InflaRx stock opened at $1.18 on Thursday. InflaRx has a 1-year low of $1.14 and a 1-year high of $5.20. The stock has a market cap of $69.48 million, a PE ratio of -1.51 and a beta of 1.26. The stock’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.53.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, research analysts expect that InflaRx will post -0.97 earnings per share for the current fiscal year.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently bought and sold shares of IFRX. Raymond James & Associates increased its position in shares of InflaRx by 18.5% during the third quarter. Raymond James & Associates now owns 162,406 shares of the company’s stock worth $484,000 after purchasing an additional 25,350 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of InflaRx by 45.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 268,915 shares of the company’s stock worth $801,000 after purchasing an additional 84,178 shares in the last quarter. 683 Capital Management LLC increased its position in shares of InflaRx by 17.5% during the third quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock worth $7,003,000 after purchasing an additional 350,000 shares in the last quarter. Affinity Asset Advisors LLC increased its position in shares of InflaRx by 35.3% during the third quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock worth $969,000 after purchasing an additional 84,897 shares in the last quarter. Finally, Alps Advisors Inc. increased its position in shares of InflaRx by 109.4% during the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after purchasing an additional 43,501 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.